Stay updated with breaking news from Early Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy,...
LYON, France, November 02, 2023--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced today that extended results from its Early Access Program of MaaT013 in 111 patients (additional 30 patients included in the Program compared to last year) with aGvHD and the design of its Phase 2b study evaluating MaaT033
With more investment in AI, computing capacity and skills, Australia’s Microsoft partners look at the opportunities ahead.
Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients.For the seventh conse...
Biophytis / Key word(s): MiscellaneousBiophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil 30-Oct-2023 / 06:00 CET/CEST Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos...